Research Analysts Issue Forecasts for PolyPid Q1 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of PolyPid in a research report issued to clients and investors on Wednesday, February 11th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($0.68) EPS and FY2029 earnings at $1.90 EPS.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07).

A number of other equities analysts also recently commented on PYPD. Citigroup reissued a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Roth Mkm reduced their price objective on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.25.

PolyPid Stock Down 3.5%

PYPD opened at $4.43 on Friday. PolyPid has a 52-week low of $2.30 and a 52-week high of $5.12. The company has a 50 day moving average of $4.37 and a two-hundred day moving average of $3.81. The company has a market cap of $70.44 million, a P/E ratio of -1.96 and a beta of 1.52.

Institutional Trading of PolyPid

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its stake in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares in the last quarter. HighTower Advisors LLC purchased a new stake in PolyPid during the 4th quarter worth approximately $44,000. Jane Street Group LLC purchased a new stake in PolyPid during the 4th quarter worth approximately $66,000. Lumbard & Kellner LLC acquired a new position in shares of PolyPid in the 2nd quarter valued at approximately $135,000. Finally, AIGH Capital Management LLC boosted its stake in shares of PolyPid by 27.0% during the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after buying an additional 253,727 shares during the last quarter. 26.47% of the stock is owned by hedge funds and other institutional investors.

More PolyPid News

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $13 price target and models significant long‑term upside (FY2028 and FY2030 estimates were raised to positive territory), which supports a bullish narrative for PYPD’s eventual commercial prospects.
• Positive Sentiment: Management’s Q4 earnings call was described as upbeat and flagged a potentially material 2026 catalyst that investors may view as a near‑term growth trigger. PolyPid Earnings Call Flags Big 2026 Catalyst
• Neutral Sentiment: Full Q4 2025 earnings call transcript and highlight coverage are available for investors who want details on pipeline timing, trial milestones and cash guidance; these provide context but may not move the stock until the 2026 catalyst is clarified. Q4 2025 Earnings Call Highlights Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright materially lowered FY2026 EPS estimates (now forecasting a larger loss: -$1.69 vs prior -$1.46) and trimmed FY2029 slightly, signaling worse near‑term profitability than previously expected — a negative for short‑term sentiment.
• Negative Sentiment: PolyPid missed Q4 EPS expectations (reported -$0.41 vs consensus -$0.34), underscoring current cash‑burn/loss trends that weigh on the share price until clinical or commercial catalysts materialize. Earnings Call Transcript

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.